Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.40 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL436724 | 0.96 | OPRL1 (0.58) | OPRL1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL435254 | 0.94 | OPRL1 (0.59) | OPRL1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL434354 | 0.91 | OPRL1 (0.57) | OPRL1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL29266754 | 0.84 | OPRL1 (0.56) | OPRL1HTR2AHTR2CHTR2BGRM2 | |
| SCHEMBL16404878 | 0.83 | OPRL1 (0.49) | OPRL1GRM2F2RL1HCRTR2 | |
| SCHEMBL28247579 | 0.83 | KDM1A (0.52) | OPRL1NOS3NOS1NOS2CHRNB2 | |
| SCHEMBL23484495 | 0.82 | OPRL1 (0.50) | OPRL1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL187795 | 0.82 | SLC6A2 (0.55) | OPRL1CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28712898 | 0.82 | OPRL1 (0.50) | OPRL1HTR2AHTR2CHTR2BCHRNB2 | |
| SCHEMBL5019341 | 0.82 | OPRL1 (0.50) | OPRL1HTR2AHTR2CHTR2BCHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3653300-A1 | OLEFIN OLIGOMERIZATION PROCESS WITH A CATALYST COMPRISING A CHROMIUM COMPLEX WITH A PHOSPHACYCLE-CONTAINING LIGAND | Dow Global Technologies LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3653299-A1 | CHROMIUM COMPLEX WITH A PHOSPHACYCLE-CONTAINING LIGAND AND OLEFIN OLIGOMERISATION CATALYST THEREFROM | Dow Global Technologies LLC (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3453452-A2 | PHOSPHACYCLE-CONTAINING LIGAND FOR CHROMIUM COMPLEX AND OLEFIN OLIGOMERISATION CATALYST THEREFROM | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-03-13 | — | — | EP | disclosed |
| CN-105431414-B | The 4 round rings formamides as nematicide | 先正达参股股份有限公司 | 2018-06-15 | — | — | CN | disclosed |
| EP-2595984-A1 | MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595985-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | Syngenta Participations AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| WO-2012010568-A1 | MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012010567-A1 | ISOXAZOLE, ISOTHIAZOLE, FURANE AND THIOPHENE COMPOUNDS AS MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-26 | — | — | WO | disclosed |
| US-8044075-B2 | IL-8 receptor antagonists | GLAXOSMITHKLINE (US) | 2011-10-25 | — | — | US | disclosed |
| US-20100298387-A1 | IL-8 Receptor Antagonists | SMITHKLINE BEECHAM CORPORATION | 2010-11-25 | — | — | US | disclosed |
| EP-2099300-A1 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2009-09-16 | — | — | EP | disclosed |
| WO-2008070707-A1 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298387-A1 | IL-8 Receptor Antagonists | CXCL8, CCR8, IL1RN | OPRL1 255/4885HTR2A 887/4885HTR2C 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.